Coca-Cola beats quarterly revenue estimates on steady soda demand
Coca-Cola beat Wall Street estimates for second-quarter revenue on Tuesday, as the beverages giant benefited from resilient demand for its sodas.
The company's comparable revenue rose 2.5 per cent to US$12.62 billion, compared with analysts' expectations of a 1.86 per cent growth to $12.54 billion, according to data compiled by LSEG.
(Reporting by Juveria Tabassum in Bengaluru; Editing by Sriraj Kalluvila)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Diabetes Clinical Trial Pipeline Experiences Rapid Expansion as Over 200+ Leading Companies Advance Novel Therapies
DelveInsight's, ' Diabetes Pipeline Insight 2025 ' report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook Key Takeaways from the Diabetes Pipeline Report In June 2025, Eli Lilly and Company announced a study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks). DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment. The leading Diabetes Companies such as vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others. Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs Diabetes Emerging Drugs Profile Cadisegliatin: vTv Therapeutics Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes. LY-3209590: Eli Lilly and Company Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes. CT-388: Roche CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Type 2 Diabetes Mellitus. HU6: Rivus Pharmaceuticals HU6 is an investigational, first-in-class oral therapy developed by Rivus Pharmaceuticals. It belongs to a new drug class called Controlled Metabolic Accelerators (CMAs), which are designed to selectively increase fat metabolism, leading to fat loss while preserving muscle mass. HU6 works by subtly increasing resting metabolism, specifically by activating a process called mitochondrial uncoupling. This process increases the oxidation of sugars and fats without reducing ATP (energy) production, resulting in the selective reduction of accumulated fat throughout the body. Currently, the drug is in the Phase II stage of development to treat Diabetes. XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. K-833: Kallyope Inc. K-833 is an investigational oral small-molecule developed by Kallyope Inc., designed as a nutrient receptor agonist for the treatment of obesity and type 2 diabetes. K-833, often studied in combination with Kallyope's other candidate K-757, targets G-protein coupled receptors (specifically GPR119), which are involved in the release of hormones that suppress appetite and regulate glucose. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. The Diabetes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment. Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs Diabetes Companies vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetes Products have been categorized under various Molecule types such as, Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers Scope of the Diabetes Pipeline Report Coverage- Global Diabetes Companies- vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others. Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Diabetes: Overview Pipeline Therapeutics Therapeutic Assessment Diabetes– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Cadisegliatin: vTv Therapeutics Drug profiles in the detailed report….. Mid-Stage Products (Phase II) CPL207280: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) KN056: Suzhou Alphamab Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetes Key Companies Diabetes Key Products Diabetes- Unmet Needs Diabetes- Market Drivers and Barriers Diabetes- Future Perspectives and Conclusion Diabetes Analyst Views Diabetes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
5 hours ago
- Globe and Mail
Slkor Micro Semicon Honors Two Sales Leaders for Consecutive Quarterly Excellence
Dual Recognition Highlights Talent Development Strategy Slkor Micro Semicon announced its dual honorees of the quarterly "Golden Navigation Outstanding Employee Award": Huang Baoling (Q2 2024) and Zhang Junjun (Q2 2025). The awards recognize exceptional sales leadership and embody Slkor's commitment to cultivating industry talent. Huang Baoling: Sustained Excellence Catalyst Appointed in 2021, Huang achieved a remarkable breakthrough in 2024: "Her poise in adversity transformed persistence into explosive growth," noted GM Song Shiqiang during the July 15, 2024 ceremony. Huang attributes success to a principle: "Endure hardships others won't to earn rewards others can't." Zhang Junjun: Leadership & Belief-Driven Results As Director of Sales Department II, Zhang was honored on July 14, 2025 for: Deputy GM He Junju presented the award, praising Zhang's "dual excellence in individual performance and team mentorship." Executive Perspective "Huang and Zhang exemplify our belief: investing in people drives technological innovation," stated GM Song Shiqiang. "Their achievements accelerate our global vision as we establish R&D hubs across Asia and Europe." About SLKOR： SLKOR, headquartered in Shenzhen, China, is a rapidly emerging national high-tech enterprise in the power semiconductor sector. With R&D centers in Beijing and Suzhou, its core technical team originates from Tsinghua University. As an innovator in silicon carbide (SiC) power device technology, SLKOR's products are widely used in new energy vehicles, photovoltaic power generation, industrial IoT, and consumer electronics, providing critical semiconductor solutions to over 10,000 clients globally. The company delivers more than 2 billion units annually, with its SiC MOSFETs and 5th-generation ultrafast recovery SBD diodes setting industry benchmarks in efficiency ratio and thermal stability. SLKOR holds over 100 invention patents and offers 2,000+ product models, continually expanding its IP portfolio across power devices, sensors, and power management ICs. Certifications including ISO 9001, EU RoHS/REACH, and CP65 compliance demonstrate the company's steadfast commitment to technological innovation, lean manufacturing, and sustainable development. Strategic Growth ContextBoth awards align with Slkor's expansion milestones: New Product Spotlight Coinciding with the recognitions, Slkor announced its SL27517A Gate Driver's competitive edge: • 4.5V-20V operating range (vs. TI UCC27517's 4.5V-18V) • Symmetrical 4A peak drive current for power MOSFETs/IGBTs • Optimized for portable devices & DC-DC converters*Free demo boards: slkoric@ Media Contact Company Name: Shenzhen SLKOR Micro Semicon Co., Ltd. Contact Person: Support Email: Send Email Phone: +86 13008868302 Address: 2010, Block A, Bairuida Building Vanke City Community Bantian Avenue, Longgang District City: Shenzhen Country: China Website:
CTV News
5 hours ago
- CTV News
Seven & i pushes back against Couche-Tard's reasons for deal talks ending
The parent company of 7-Eleven has pushed back against the reasons Alimentation Couche-Tard Inc. gave for why a takeover deal never materialized. Couche-Tard said last week that it was ending a yearlong effort to buy Seven & i Holdings Co. Ltd., saying there had been no sincere or constructive engagement from the Japan-based company over a potential deal. Seven & i's special board committee said Couche-Tard's claims were highly misleading as it rejected the characterization in a letter issued Tuesday. 'We consistently engaged in good faith, and we are disappointed that [Couche-Tard] has decided to walk away from these discussions. We are further disappointed that they have done so in a way that completely mischaracterizes both our engagement and the significant hurdles this transaction faced that they were not committed to resolving,' the letter said. It said that from the start, Couche-Tard didn't take competition concerns seriously, and didn't present a credible plan as to how those concerns would be addressed. Given the scale of the two convenience store chains, Seven & i noted that regulators would likely require a 'very significant divestiture' before approving a deal, but it said Couche-Tard was not able to provide a plan on who could be the buyer or how such a deal would work. Couche-Tard said in its letter last week that it received multiple indications of interest from potential buyers of divested assets, but that Seven & i didn't provide the needed additional information to move those talks forward. The Laval-based company also said in its letter that there was not only a lack of engagement, but also a 'calculated campaign of obfuscation and delay' from Seven & i that reinforced its governance concerns. Couche-Tard initially met with Seven & i on July 23, 2024, with the 7-Eleven owner making talks public in August. The company rejected Couche-Tard's initial offer reportedly worth about US$38.6 billion, leading Couche-Tard to submit a higher offer that media reports suggest was worth US$47 billion. Soon after the second bid, Junro Ito, a member of the family that helped found the company, put forward a new management buyout proposal. But Seven & i resumed talks with Couche-Tard after the family-led effort failed to secure financing. Even as talks resumed, Seven & i announced in March a plan to sell billions of dollars worth of its non-convenience store assets to Bain Capital and launch an initial public offering of its North American 7-Eleven business. The two sides went back and forth with concerns about regulatory approval and a lack of engagement, until on July 16 Couche-Tard said it was ending its bid. Seven & i said it did engage faithfully in the process, and held ten virtual meetings along with the two that Couche-Tard referenced. It said its governance was up to the task, and it was ready to go the distance to determine if a solution could be found. The criticism, including on scripted meetings, demonstrates an unfortunate lack of knowledge of the Japanese market, the board said. 'To suggest that our management presentations were scripted is to misunderstand Japanese culture. Sometimes being different isn't wrong or an act of resistance.' Seven and i said it was disappointed in Couche-Tard ending the process but that it wasn't surprised, pointing to both the regulatory hurdles, and the wider economic issues that have weighed on Couche-Tard. 'We understand and respect the operational, financial and market challenges their business is facing, and we recognize how financing markets have changed. But there is no need to blame Seven & i for that reality.' Couche-Tard's share price had gone from trading around $82 a year ago to about $69 before it announced an end to its deal efforts, which sent its share price up to about $77 to give the convenience store giant about a $73 billion market capitalization. This report by The Canadian Press was first published July 23, 2025. Ian Bickis, The Canadian Press
